文献速递糖尿病肥胖与代谢综合征

卒中前减重通过GLP-1R和NPY2R激活改善雄性糖尿病小鼠卒中后功能恢复

Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
PubMed 文献 · Diabetologia · 2025-10-15

该研究在肥胖2型糖尿病雄性小鼠中探究卒中前药物减重对卒中后恢复的作用。使用司美格鲁肽和BI8271诱导减重后行短暂大脑中动脉闭塞,发现GLP-1R激活及GLP-1/NPY2双激活可改善卒中后恢复,且恢复与外周IGF-1水平负相关;急性给药亦可不依赖代谢效应提供神经保护。

要点

  • 卒中前减重可改善糖尿病小鼠卒中后功能恢复
  • GLP-1与NPY2双激活减重效果更强且恢复更优
  • 卒中后急性给药可独立于代谢效应提供神经保护

核心结论

  • 卒中前通过GLP-1R激活减重、更有效通过GLP-1和NPY2受体双激活减重,是位于血糖调控上游的可成药机制,可实现卒中后恢复。
  • 2型糖尿病小鼠卒中后恢复与外周IGF-1水平呈负相关。
  • GLP-1R和NPY2R激活若在卒中后急性给药,可不依赖代谢效应通过急性神经保护改善卒中恢复。

研究设计与样本

  • C57BL/6J雄性小鼠高脂饮食5个月诱导肥胖及2型糖尿病特征(高血糖和胰岛素抵抗)。
  • 通过4周司美格鲁肽和/或BI8271给药诱导减重,并以PBS对照转为标准饮食达到相同体重范围和减重百分比作为减重对照。
  • 随后行短暂大脑中动脉闭塞(tMCAO),主要结局为握力和侧化感觉运动整合恢复,次要结局为卒中体积和血清IGF-1。
  • 另设研究在tMCAO再灌注后1和24小时注射司美格鲁肽和/或BI8271,评估急性神经保护。

主要发现

  • 卒中前GLP-1R激活减重可改善卒中后恢复,GLP-1和NPY2受体双激活效果更强。
  • 2型糖尿病小鼠卒中后恢复与外周IGF-1水平呈负相关。
  • 卒中后急性给予GLP-1R和NPY2R激活剂可独立于代谢效应改善卒中恢复。

临床怎么用

  • 临床使用的2型糖尿病治疗药物可能具有预防性作用,通过减重和急性神经保护双重药理作用改善卒中结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes is associated with worsened stroke outcome and lasting disability. The underlying mechanisms are undetermined, and no therapy is available. We experimentally investigated whether pharmacologically targeting obesity, which is highly prevalent in type 2 diabetes, before stroke enhances neurological recovery in type 2 diabetes. To induce weight loss, we employed the glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide and the neuropeptide Y receptor Y2 (NPY2R) agonist BI8271, which potentiates GLP-1R-mediated weight loss. We also investigated potential acute neuroprotective effects induced by these treatments, independently of metabolic regulation. METHODS: C57BL/6J mice were fed with a high-fat diet for 5 months to induce obesity and features of type 2 diabetes (i.e. hyperglycaemia and insulin resistance). Weight loss was induced by 4-week administration of semaglutide and/or BI8271. As a control for the effect of weight loss, a vehicle (PBS)-treated group was switched to standard diet to achieve the same weight range and the same percentage weight loss within the same time frame as those receiving semaglutide/BI8271. Thereafter, mice were subjected to stroke by transient middle cerebral artery occlusion (tMCAO). Stroke recovery (the primary outcome) was assessed by measuring the recovery of grip strength and the lateralised sensorimotor integration. Brains and serum were collected, and stroke volume and serum IGF-1 levels were quantified (secondary outcomes). In additional studies, type 2 diabetic mice were subjected to tMCAO and injected with semaglutide and/or BI8271 1 and 24 h after reperfusion. Acute neuroprotection (the primary outcome) was assessed by a grip strength test and by quantifying stroke volume and the number of surviving neuronal nuclear marker (NeuN)-positive neurons. RESULTS: We report that pre-stroke weight loss by GLP-1R activation, and more potently by dual co-activation of GLP-1 and NPY2 receptors, is a pharmacologically targetable mechanism, upstream of glycaemic regulation, through which post-stroke recovery is achieved. Moreover, we show that post-stroke recovery in type 2 diabetes is inversely associated with peripheral IGF-1 levels. Finally, GLP-1R and NPY2R activation can also improve stroke recovery through acute neuroprotection if they are given acutely after stroke, independently of their metabolic effects. CONCLUSIONS/INTERPRETATION: The diabetes and obesity epidemics are increasing the incidence of stroke, and consequently the need for treatments to improve stroke outcome. Our results indicate that clinically used type 2 diabetes treatments could be employed in a preventive role to improve stroke outcome by exerting dual pharmacological action: weight loss and acute neuroprotection. These findings could have novel therapeutic implications for many people.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Vercalsteren E, Karampatsi D, Neicu M, et al. Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models. Diabetologia. 2025. PMID: 41094027. doi:10.1007/s00125-025-06567-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。